Rise Therapeutics Advanced Clinical Trial for R-5780

The company has initiated the dose expansion phase of its trial targeting refractory tumors.

Updated on Sept. 22, 2026 in Biotech

Bold flat-color editorial illustration of a crystalline medical vial, representing the advancement of clinical trial drug development. — Rockville-based Rise Therapeutics has advanced its R-5780 drug candidate into the dose expansion phase following a positive review of safety data. AI Illustration. Upload story photo >

Live Poll

Would you prioritize investing in companies developing new treatments for cancer patients with unmet needs?

Rockville-based Rise Therapeutics has completed the dose escalation portion of its Phase 1 clinical trial for the drug candidate R-5780. The study has now moved into a dose expansion stage to further evaluate the treatment in cancer patients.

Why it matters

The trial aims to re-sensitize tumors that have become resistant to existing PD-1 immune checkpoint inhibitor therapies. This approach addresses a significant gap in care for the majority of advanced cancer patients who do not respond to standard immunotherapy.

The clinical trial, registered as NCT06398418, focuses on testing drug exposure and safety metrics in up to 33 participants. The expansion phase uses the highest fixed dose determined during the recently completed escalation period.

The players

Rise Therapeutics

Headquartered in Rockville, this biotechnology company focuses on developing novel treatments to overcome immunotherapy resistance.

The details

An independent Data Monitoring Committee reviewed safety data from the initial study phase before approving the move to the expansion stage. The trial specifically recruits patients with advanced cancer whose tumors no longer respond to PD-1 inhibitor therapy.

September 22, 2026: Rise Therapeutics announced the completion of the dose escalation phase.
2026: The global immune checkpoint inhibitor market reached a valuation of $49.8 billion.
2030: The global market for these inhibitors is projected to reach $154.3 billion.

The Tech Race

This development follows the documented trend that only 20% of advanced cancer patients respond to checkpoint inhibitor therapy. The trial attempts to improve on this established benchmark by specifically targeting tumors that have developed resistance to existing PD-1 therapies.

This trial represents a potential new treatment pathway for patients who have exhausted standard immunotherapy options. Success in this program could eventually provide new clinical alternatives for the high percentage of patients currently underserved by existing checkpoint inhibitors.

The takeaway

The transition to a dose expansion phase marks a significant milestone in testing whether R-5780 can effectively overcome treatment resistance. As market projections estimate sector growth to reach $154.3 billion by 2030, this trial remains a key indicator for future immunotherapy advancements.